Inosine growth factor shows promise for stroke:
This article was originally published in Clinica
Executive Summary
Boston Life Sciences' nerve growth factor Inosine, for treating stroke, can induce nerve fibre growth, stimulate brain rewiring and improve motor functions, an animal study has shown. The findings were published in the Proceedings of the National Academy of Sciences (June 25). Inosine, which so far, appears to have no apparent side effects in animals, has potential as a novel nerve regeneration approach to treatment of stroke and other types of brain injuries, said the Boston, Massachusetts firm.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.